Trial reportBJS open2025
Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial.
Trial report in BJS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02614534 (Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
backgroundDespite adjuvant systemic chemotherapy after surgical resection in patients with pT4 stage colon cancer, a high percentage of them will develop peritoneal metastases. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option with the goal of preventing metachronous peritoneal metastases. The aim of this study was to report the longer-term outcomes of peritoneal control with the use of intraoperative HIPEC based on mitomycin C after the last enrolled patient of the HIPECT4 trial reached 36 months follow-up.
methodsBetween November 2015 and March 2021, patients with resectable primary clinical T4 N0-2M0 were included and randomized (1:1) to either adjuvant HIPEC with mitomycin C (30 mg/m2, 60 minutes) or standard treatment. The primary endpoint was locoregional control at 36 months. Kaplan-Meier survival analysis with a log-rank test was used to compare the two study groups.
resultsA total of 184 patients were included and followed up at 36 months. The locoregional control rate was improved with HIPEC compared with adjuvant chemotherapy alone (hazard ratio 0.19, 95% confidence interval 0.04 to 0.86; P = 0.031). Three years overall survival and disease-free survival did not differ between patients assigned to the HIPEC and control groups. Subgroup analysis showed better locoregional control with the use of HIPEC for patients with definitive pT4 colon cancer (hazard ratio 0.08, 0.01 to 0.65; P = 0.017) and per protocol (receiving adjuvant chemotherapy) patients (hazard ratio 0.18, 0.04 to 0.83; P = 0.028). The pattern of recurrence was modified significantly using HIPEC with less peritoneal relapse.
conclusionThe long-term outcome analysis of the HIPECT4 trial demonstrated that using mitomycin C-based HIPEC reduced peritoneal recurrence in patients with locally advanced colon cancer without increasing toxicity. However, there was no difference in overall survival and disease-free survival. REGISTRATION NUMBER: NCT02614534 (https://clinicaltrials.gov/).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.